Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 9/20 | 0.50 |
| ▸ | FLT4 | P35916 | 9/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892243 | 0.88 | ALDH1A1 (0.51) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL18547926 | 0.87 | ALDH1A1 (0.65) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL1258694 | 0.87 | LMNA (0.54) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL29541454 | 0.86 | ALDH1A1 (0.49) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL1018760 | 0.85 | CA2 (0.55) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL16908508 | 0.83 | KDM4E (0.45) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL16908533 | 0.82 | ALDH1A1 (0.50) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL3121869 | 0.82 | ALDH1A1 (0.44) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL16908460 | 0.82 | ALDH1A1 (0.43) | FLT1FLT4KDRALDH1A1TSHR | |
| SCHEMBL3715447 | 0.80 | FLT1 (0.48) | FLT1FLT4KDRALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| CN-112759559-A | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9790183-B2 | Pyridyl inhibitors of hedgehog signalling | GENENTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-1403247-A1 | N-Alkanoylphenylalanine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| EP-1109560-B1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6525050-B1 | Inhibit the enzyme aminoimidazole carboxamide ribonucleotide formyl transferase; antiproliferative agents; antitumor, antiinflammatory, antipsoriatic, and/or immunosuppressive | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1109560-A4 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1109560-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000013688-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1037/4885FLT4 1015/4885KDR 1431/4885 |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | FLT1 2673/4885FLT4 2945/4885KDR 2915/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1037/4885FLT4 1015/4885KDR 1431/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1064/4885FLT4 1098/4885KDR 1492/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | FLT1 2739/4885FLT4 3039/4885KDR 2993/4885 |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1037/4885FLT4 1015/4885KDR 1431/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1037/4885FLT4 1015/4885KDR 1431/4885 |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FLT1 1037/4885FLT4 1015/4885KDR 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.